S&P 500   3,310.11 (+1.19%)
DOW   26,659.11 (+0.52%)
QQQ   276.39 (+1.75%)
AAPL   115.32 (+3.71%)
MSFT   204.72 (+1.01%)
FB   280.83 (+4.92%)
GOOGL   1,556.88 (+3.05%)
AMZN   3,211.01 (+1.52%)
TSLA   410.83 (+1.18%)
NVDA   520.96 (+3.14%)
BABA   312.56 (+1.50%)
CGC   18.78 (+2.40%)
GE   7.37 (-0.67%)
MU   50.48 (+0.96%)
AMD   78.02 (+2.12%)
T   26.76 (+0.98%)
F   7.90 (+2.60%)
ACB   4.09 (+6.79%)
GILD   58.53 (-0.32%)
NFLX   504.21 (+3.70%)
NIO   31.99 (+16.28%)
BA   148.29 (+0.10%)
DIS   121.54 (+2.59%)
S&P 500   3,310.11 (+1.19%)
DOW   26,659.11 (+0.52%)
QQQ   276.39 (+1.75%)
AAPL   115.32 (+3.71%)
MSFT   204.72 (+1.01%)
FB   280.83 (+4.92%)
GOOGL   1,556.88 (+3.05%)
AMZN   3,211.01 (+1.52%)
TSLA   410.83 (+1.18%)
NVDA   520.96 (+3.14%)
BABA   312.56 (+1.50%)
CGC   18.78 (+2.40%)
GE   7.37 (-0.67%)
MU   50.48 (+0.96%)
AMD   78.02 (+2.12%)
T   26.76 (+0.98%)
F   7.90 (+2.60%)
ACB   4.09 (+6.79%)
GILD   58.53 (-0.32%)
NFLX   504.21 (+3.70%)
NIO   31.99 (+16.28%)
BA   148.29 (+0.10%)
DIS   121.54 (+2.59%)
S&P 500   3,310.11 (+1.19%)
DOW   26,659.11 (+0.52%)
QQQ   276.39 (+1.75%)
AAPL   115.32 (+3.71%)
MSFT   204.72 (+1.01%)
FB   280.83 (+4.92%)
GOOGL   1,556.88 (+3.05%)
AMZN   3,211.01 (+1.52%)
TSLA   410.83 (+1.18%)
NVDA   520.96 (+3.14%)
BABA   312.56 (+1.50%)
CGC   18.78 (+2.40%)
GE   7.37 (-0.67%)
MU   50.48 (+0.96%)
AMD   78.02 (+2.12%)
T   26.76 (+0.98%)
F   7.90 (+2.60%)
ACB   4.09 (+6.79%)
GILD   58.53 (-0.32%)
NFLX   504.21 (+3.70%)
NIO   31.99 (+16.28%)
BA   148.29 (+0.10%)
DIS   121.54 (+2.59%)
S&P 500   3,310.11 (+1.19%)
DOW   26,659.11 (+0.52%)
QQQ   276.39 (+1.75%)
AAPL   115.32 (+3.71%)
MSFT   204.72 (+1.01%)
FB   280.83 (+4.92%)
GOOGL   1,556.88 (+3.05%)
AMZN   3,211.01 (+1.52%)
TSLA   410.83 (+1.18%)
NVDA   520.96 (+3.14%)
BABA   312.56 (+1.50%)
CGC   18.78 (+2.40%)
GE   7.37 (-0.67%)
MU   50.48 (+0.96%)
AMD   78.02 (+2.12%)
T   26.76 (+0.98%)
F   7.90 (+2.60%)
ACB   4.09 (+6.79%)
GILD   58.53 (-0.32%)
NFLX   504.21 (+3.70%)
NIO   31.99 (+16.28%)
BA   148.29 (+0.10%)
DIS   121.54 (+2.59%)
Log in
NASDAQ:NXTC

NextCure Stock Forecast, Price & News

$10.41
+0.33 (+3.27 %)
(As of 10/29/2020 04:49 PM ET)
Add
Compare
Today's Range
$9.87
Now: $10.41▼
$10.58
50-Day Range
$8.21
MA: $10.11▼
$12.43
52-Week Range
$7.91
Now: $10.41▼
$109.00
Volume171,120 shs
Average Volume466,426 shs
Market Capitalization$286.45 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.48
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase 2 clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, is a novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules that targets a novel member of the B7-family of immunomodulatory proteins; and an antibody in preclinical development targeting an immune modulator that is expressed in inflamed tissue and the tumor microenvironment in various tumor types. NextCure, Inc. has a license agreement with Yale University; and a research and development collaboration with Eli Lilly and Company. The company was founded in 2015 and is headquartered in Beltsville, Maryland.
Read More

Beat the Market (BTM) Rank™

Analyst Opinion: 3.2Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.51 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NXTC
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.nextcure.com
Phone240-399-4900
Employees69

Debt

Debt-to-Equity Ratio0.01
Current Ratio37.68
Quick Ratio37.68

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$6.35 million
Price / Sales45.11
Cash FlowN/A
Price / Cash FlowN/A
Book Value$14.13 per share
Price / Book0.74

Profitability

EPS (Most Recent Fiscal Year)($2.15)
Net Income$-33,740,000.00
Net Margins-65.22%
Return on Equity-8.43%
Return on Assets-7.80%

Miscellaneous

Outstanding Shares27,517,000
Market Cap$286.45 million
Next Earnings Date11/10/2020 (Estimated)
OptionableNot Optionable
$10.41
+0.33 (+3.27 %)
(As of 10/29/2020 04:49 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NXTC News and Ratings via Email

Sign-up to receive the latest news and ratings for NXTC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











NextCure (NASDAQ:NXTC) Frequently Asked Questions

How has NextCure's stock been impacted by COVID-19?

NextCure's stock was trading at $38.22 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, NXTC stock has decreased by 72.8% and is now trading at $10.41.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of NextCure?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NextCure in the last year. There are currently 5 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for NextCure.

When is NextCure's next earnings date?

NextCure is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for NextCure.

How were NextCure's earnings last quarter?

NextCure, Inc. (NASDAQ:NXTC) issued its quarterly earnings results on Thursday, August, 6th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.50) by $0.03. NextCure had a negative return on equity of 8.43% and a negative net margin of 65.22%.
View NextCure's earnings history.

What price target have analysts set for NXTC?

9 equities research analysts have issued 12 month target prices for NextCure's stock. Their forecasts range from $11.00 to $87.00. On average, they expect NextCure's stock price to reach $32.70 in the next twelve months. This suggests a possible upside of 214.1% from the stock's current price.
View analysts' price targets for NextCure.

Who are some of NextCure's key competitors?

Some companies that are related to NextCure include MacroGenics (MGNX), Cytokinetics (CYTK), Applied Molecular Transport (AMTI), Endo International (ENDP), Indivior (INVVY), Phathom Pharmaceuticals (PHAT), Retrophin (RTRX), BioXcel Therapeutics (BTAI), Nabriva Therapeutics (NBRV), Nkarta (NKTX), Supernus Pharmaceuticals (SUPN), Northwest Biotherapeutics (NWBO), Repare Therapeutics (RPTX), Intercept Pharmaceuticals (ICPT) and Rhythm Pharmaceuticals (RYTM).
View all competitors.

What other stocks do shareholders of NextCure own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NextCure investors own include SCYNEXIS (SCYX), ADMA Biologics (ADMA), Matinas BioPharma (MTNB), BioNano Genomics (BNGO), Novan (NOVN), OrganiGram (OGI), Kadmon (KDMN), Sorrento Therapeutics (SRNE), Vaxart (VXRT) and DHT (DHT).

Who are NextCure's key executives?

NextCure's management team includes the following people:
  • Mr. Michael S. Richman, Co-Founder, CEO, Pres & Director (Age 59, Pay $625.68k)
  • Dr. Solomon Langermann, Chief Scientific Officer (Age 61, Pay $459.11k)
  • Dr. Lieping Chen M.D., Ph.D., Co-Founder & Chairman of Scientific Advisory Board (Age 63)
  • Mr. Steven P. Cobourn CPA, CPA, Chief Financial Officer (Age 57)
  • Dr. Timothy Mayer Ph.D., Chief Operating Officer (Age 56)

When did NextCure IPO?

(NXTC) raised $75 million in an initial public offering (IPO) on Thursday, May 9th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofAMerrill Lynch, Pierce and Piper Jaffray acted as the underwriters for the IPO.

What is NextCure's stock symbol?

NextCure trades on the NASDAQ under the ticker symbol "NXTC."

Who are NextCure's major shareholders?

NextCure's stock is owned by many different institutional and retail investors. Top institutional investors include Canaan Partners X LLC (6.22%). Company insiders that own NextCure stock include Sofinnova Venture Partners Ix,, Stella Xu and X LP Canaan.
View institutional ownership trends for NextCure.

Which institutional investors are selling NextCure stock?

NXTC stock was sold by a variety of institutional investors in the last quarter, including Canaan Partners X LLC.
View insider buying and selling activity for NextCure.

How do I buy shares of NextCure?

Shares of NXTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is NextCure's stock price today?

One share of NXTC stock can currently be purchased for approximately $10.41.

How big of a company is NextCure?

NextCure has a market capitalization of $286.45 million and generates $6.35 million in revenue each year. The company earns $-33,740,000.00 in net income (profit) each year or ($2.15) on an earnings per share basis. NextCure employs 69 workers across the globe.

What is NextCure's official website?

The official website for NextCure is www.nextcure.com.

How can I contact NextCure?

NextCure's mailing address is 9000 VIRGINIA MANOR ROAD SUITE 200, BELTSVILLE MD, 20705. The company can be reached via phone at 240-399-4900 or via email at [email protected]

This page was last updated on 10/29/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.